| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Dean F Wong, Hiroto Kuwabara, Andrew G Horti, Vanessa Raymont, James Brasic, Maria Guevara, Weiguo Ye, Robert F Dannals, Hayden T Ravert, Ayon Nandi, Arman Rahmim, Jeffrey E Ming, Igor Grachev, Christine Roy, Nicola Cascell. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. NeuroImage. vol 52. issue 4. 2010-12-17. PMID:20406692. |
several studies have examined the link between the cannabinoid cb1 receptor and several neuropsychiatric illnesses, including schizophrenia. |
2010-12-17 |
2023-08-12 |
human |
| Stephen M Eggan, Samuel R Stoyak, Christopher D Verrico, David A Lewi. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 35. issue 10. 2010-12-06. PMID:20555313. |
cannabinoid cb1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder. |
2010-12-06 |
2023-08-12 |
human |
| Stephen M Eggan, Samuel R Stoyak, Christopher D Verrico, David A Lewi. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 35. issue 10. 2010-12-06. PMID:20555313. |
we recently showed that measures of cannabinoid 1 receptor (cb1r) mrna and protein were significantly reduced in dorsolateral prefrontal cortex (dlpfc) area 9 in schizophrenia subjects relative to matched normal comparison subjects. |
2010-12-06 |
2023-08-12 |
human |
| Hiroki Ishiguro, Yasue Horiuchi, Maya Ishikawa, Minori Koga, Keiko Imai, Yoshimi Suzuki, Miyuki Morikawa, Toshiya Inada, Yuichiro Watanabe, Makoto Takahashi, Toshiyuki Someya, Hiroshi Ujike, Nakao Iwata, Norio Ozaki, Emmanuel S Onaivi, Hiroshi Kunugi, Tsukasa Sasaki, Masanari Itokawa, Makoto Arai, Kazuhiro Niizato, Shyuji Iritani, Izumi Naka, Jun Ohashi, Akiyoshi Kakita, Hitoshi Takahashi, Hiroyuki Nawa, Tadao Arinam. Brain cannabinoid CB2 receptor in schizophrenia. Biological psychiatry. vol 67. issue 10. 2010-07-22. PMID:19931854. |
brain cannabinoid cb2 receptor in schizophrenia. |
2010-07-22 |
2023-08-12 |
Not clear |
| Hiroki Ishiguro, Yasue Horiuchi, Maya Ishikawa, Minori Koga, Keiko Imai, Yoshimi Suzuki, Miyuki Morikawa, Toshiya Inada, Yuichiro Watanabe, Makoto Takahashi, Toshiyuki Someya, Hiroshi Ujike, Nakao Iwata, Norio Ozaki, Emmanuel S Onaivi, Hiroshi Kunugi, Tsukasa Sasaki, Masanari Itokawa, Makoto Arai, Kazuhiro Niizato, Shyuji Iritani, Izumi Naka, Jun Ohashi, Akiyoshi Kakita, Hitoshi Takahashi, Hiroyuki Nawa, Tadao Arinam. Brain cannabinoid CB2 receptor in schizophrenia. Biological psychiatry. vol 67. issue 10. 2010-07-22. PMID:19931854. |
neural endocannabinoid function appears to be involved in schizophrenia. |
2010-07-22 |
2023-08-12 |
Not clear |
| Daniela Parolaro, Natalia Realini, Daniela Vigano, Cinzia Guidali, Tiziana Rubin. The endocannabinoid system and psychiatric disorders. Experimental neurology. vol 224. issue 1. 2010-06-28. PMID:20353783. |
the present review summarizes the latest information on the role and the pharmacological modulation of the endocannabinoid system in mood disorders and its potential implication in psychotic disorders such as schizophrenia. |
2010-06-28 |
2023-08-12 |
Not clear |
| Daniela Parolaro, Natalia Realini, Daniela Vigano, Cinzia Guidali, Tiziana Rubin. The endocannabinoid system and psychiatric disorders. Experimental neurology. vol 224. issue 1. 2010-06-28. PMID:20353783. |
moreover several lines of experimental and clinical evidence point to a dysregulation of the endocannabinoid system in schizophrenia. |
2010-06-28 |
2023-08-12 |
Not clear |
| Alexandre Seillier, Tushar Advani, Tommaso Cassano, Julie G Hensler, Andrea Giuffrid. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. The international journal of neuropsychopharmacology. vol 13. issue 3. 2010-06-24. PMID:19607756. |
the 'cannabinoid hypothesis' of schizophrenia tulates that over-activity of the endocannabinoid system might contribute to the aetiology of schizophrenia. |
2010-06-24 |
2023-08-12 |
rat |
| Alexandre Seillier, Tushar Advani, Tommaso Cassano, Julie G Hensler, Andrea Giuffrid. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. The international journal of neuropsychopharmacology. vol 13. issue 3. 2010-06-24. PMID:19607756. |
in keeping with this hypothesis, increased expression of cb1 receptors, elevation of the endocannabinoid anandamide (aea) and cannabinoid-induced cognitive changes have been reported in animal models of schizophrenia and psychotic patients. |
2010-06-24 |
2023-08-12 |
rat |
| Alexandre Seillier, Tushar Advani, Tommaso Cassano, Julie G Hensler, Andrea Giuffrid. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. The international journal of neuropsychopharmacology. vol 13. issue 3. 2010-06-24. PMID:19607756. |
in this study we measured brain endocannabinoid levels and [35s]gtpgammas binding stimulated by the cb receptor agonist cp55,940 in rats undergoing withdrawal from subchronic administration of phencyclidine (pcp), a well-established pharmacological model of schizophrenia. |
2010-06-24 |
2023-08-12 |
rat |
| Patrik Roser, Franz X Vollenweider, Wolfram Kawoh. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 11. issue 2 Pt 2. 2010-06-14. PMID:20218784. |
delta(9)-tetrahydrocannabinol (delta(9)-thc), the principal psychoactive constituent of the cannabis sativa plant, and other agonists at the central cannabinoid (cb(1)) receptor may induce characteristic psychomotor effects, psychotic reactions and cognitive impairment resembling schizophrenia. |
2010-06-14 |
2023-08-12 |
human |
| Tarik Ugur, Marius Bartels, Bernhard Kis, Norbert Scherbau. Psychosis following anti-obesity treatment with rimonabant. Obesity facts. vol 1. issue 2. 2010-02-26. PMID:20054169. |
in this report, we present the case of a patient with a relapse of schizophrenia following an episode of depression and increased anxiety after antiobesity treatment with rimonabant, a cannabinoid type 1 receptor antagonist. |
2010-02-26 |
2023-08-12 |
Not clear |
| Maria Sabrina Spano, Paola Fadda, Roberto Frau, Liana Fattore, Walter Fratt. Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 20. issue 1. 2010-02-24. PMID:19854030. |
we investigated the correlation between voluntary cannabinoid consumption and behavioral traits in an animal model of schizophrenia. |
2010-02-24 |
2023-08-12 |
rat |
| Maria Sabrina Spano, Paola Fadda, Roberto Frau, Liana Fattore, Walter Fratt. Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 20. issue 1. 2010-02-24. PMID:19854030. |
a parallel study performed in animals receiving win on a non-voluntary basis (experimenter-given) confirmed an ameliorating effect of cannabinoid administration on the symptoms of schizophrenia induced by pcp. |
2010-02-24 |
2023-08-12 |
rat |
| Daniela Vigano, Cinzia Guidali, Stefania Petrosino, Natalia Realini, Tiziana Rubino, Vincenzo Di Marzo, Daniela Parolar. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. The international journal of neuropsychopharmacology. vol 12. issue 5. 2010-02-12. PMID:18789179. |
involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. |
2010-02-12 |
2023-08-12 |
rat |
| Daniela Vigano, Cinzia Guidali, Stefania Petrosino, Natalia Realini, Tiziana Rubino, Vincenzo Di Marzo, Daniela Parolar. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. The international journal of neuropsychopharmacology. vol 12. issue 5. 2010-02-12. PMID:18789179. |
recent advances in the neurobiology of cannabinoids have renewed interest in the association between cannabis and schizophrenia. |
2010-02-12 |
2023-08-12 |
rat |
| Daniela Vigano, Cinzia Guidali, Stefania Petrosino, Natalia Realini, Tiziana Rubino, Vincenzo Di Marzo, Daniela Parolar. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. The international journal of neuropsychopharmacology. vol 12. issue 5. 2010-02-12. PMID:18789179. |
in this region, we observed a significant reduction in gtpgammas binding (-41%) accompanied by an increase in the levels of the endocannabinoid 2-ag (+38%) in pcp-treated rats, suggesting that a maladaptation of the endocannabinoid system might contribute to the glutamatergic-related cognitive symptoms encountered in schizophrenia disorders. |
2010-02-12 |
2023-08-12 |
rat |
| Leyre Urigüen, M Julia García-Fuster, Luis F Callado, Benito Morentin, Romano La Harpe, Vicent Casadó, Carmen Lluis, Rafael Franco, Jesús A García-Sevilla, J Javier Mean. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology. vol 206. issue 2. 2009-12-22. PMID:19652957. |
immunodensity and mrna expression of a2a adenosine, d2 dopamine, and cb1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. |
2009-12-22 |
2023-08-12 |
human |
| Ismael Galve-Roperh, Javier Palazuelos, Tania Aguado, Manuel Guzmá. The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. European archives of psychiatry and clinical neuroscience. vol 259. issue 7. 2009-11-23. PMID:19588184. |
potential implications of these new findings, such as the participation of the endocannabinoid system in the pathogenesis of neurodevelopmental disorders (e.g., schizophrenia) and the regulation of neurogenesis in brain depression, are discussed herein. |
2009-11-23 |
2023-08-12 |
Not clear |
| Deepak Cyril D'Souz. Cannabinoids and psychosis. International review of neurobiology. vol 78. 2009-11-13. PMID:17349865. |
on the other hand, the large majority of individuals exposed to cannabinoids do not experience psychosis or develop schizophrenia and the rates of schizophrenia have not increased commensurate with the increase in rates of cannabis use. |
2009-11-13 |
2023-08-12 |
Not clear |